Alzamend Neuro Files S-1 for Potential Stock Offering
Ticker: ALZN · Form: S-1 · Filed: Jun 3, 2024 · CIK: 1677077
| Field | Detail |
|---|---|
| Company | Alzamend Neuro, INC. (ALZN) |
| Form Type | S-1 |
| Filed Date | Jun 3, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.0001, $0.59, $35 million, $2.5 million, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: s-1, registration-statement, capital-raise, biotech
TL;DR
Alzamend Neuro just filed an S-1, looks like they're raising cash for their Alzheimer's drug pipeline.
AI Summary
Alzamend Neuro, Inc. filed an S-1 registration statement on June 3, 2024, to register an unspecified number of securities. The company, headquartered in Atlanta, GA, is focused on developing treatments for neurological and psychiatric disorders. This filing indicates a potential offering of new shares to raise capital for its operations and research.
Why It Matters
This S-1 filing signals Alzamend Neuro's intent to raise capital, which could fund its research and development efforts for neurological treatments, potentially impacting the future of Alzheimer's and other related disease therapies.
Risk Assessment
Risk Level: medium — As a clinical-stage biopharmaceutical company, Alzamend Neuro faces significant risks related to drug development, regulatory approval, and market adoption.
Key Numbers
- 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)
- 811822909 — IRS Number (Company's Employer Identification Number.)
Key Players & Entities
- Alzamend Neuro, Inc. (company) — Registrant
- Stephan Jackman (person) — Chief Executive Officer
- Henry Nisser (person) — Executive Vice President and General Counsel
- Kenneth A. Schlesinger (person) — Legal Counsel
- 333-279920 (dollar_amount) — SEC File Number
FAQ
What is the purpose of this S-1 filing for Alzamend Neuro, Inc.?
The S-1 filing is a registration statement filed with the SEC to register securities for a potential public offering, indicating the company's intent to raise capital.
When was this S-1 filing submitted?
The S-1 filing was submitted on June 3, 2024.
What is Alzamend Neuro, Inc.'s primary business focus?
Alzamend Neuro, Inc. is focused on developing treatments for neurological and psychiatric disorders, as indicated by its SIC code 2834 (Pharmaceutical Preparations).
Who are the key executives mentioned in the filing?
Key executives mentioned include Stephan Jackman (Chief Executive Officer) and Henry Nisser (Executive Vice President and General Counsel).
Where is Alzamend Neuro, Inc. headquartered?
Alzamend Neuro, Inc. is headquartered in Atlanta, Georgia, with its principal executive offices located at 3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, GA 30326.
Filing Stats: 4,580 words · 18 min read · ~15 pages · Grade level 16.6 · Accepted 2024-06-03 16:30:49
Key Financial Figures
- $0.0001 — 0,000 shares of common stock, par value $0.0001 per share (the "Common Stock"), of Alza
- $0.59 — orted by The Nasdaq Capital Market, was $0.59 per share. We are a "smaller reporting
- $35 million — LS") for our Common Stock was below the $35 million minimum MVLS requirement for continued
- $2.5 million — requires stockholder equity of at least $2.5 million (or an alternative listing standard), a
- $1.00 — e for the Common Stock had closed below $1.00 per share for the previous 30 consecuti
Filing Documents
- d63244s1.htm (S-1) — 243KB
- ex5_1.htm (EX-5.1) — 11KB
- ex21_1.htm (EX-21.1) — 1KB
- ex23_1.htm (EX-23.1) — 3KB
- ex107.htm (EX-FILING FEES) — 33KB
- alzamendlogo_med.jpg (GRAPHIC) — 24KB
- olshan_footer.jpg (GRAPHIC) — 5KB
- olshanaddress_header.jpg (GRAPHIC) — 10KB
- olshanlogo_header.jpg (GRAPHIC) — 7KB
- olshanwebaddy_footer.jpg (GRAPHIC) — 6KB
- 0001214659-24-010447.txt ( ) — 365KB
RISK FACTORS
RISK FACTORS 5 PRIVATE PLACEMENT 8
DESCRIPTION OF SECURITIES BEING OFFERED
DESCRIPTION OF SECURITIES BEING OFFERED 12 SELLING STOCKHOLDER 13 PLAN OF DISTRIBUTION 14 LEGAL MATTERS 15 EXPERTS 15 INFORMATION INCORPORATED BY REFERENCE 15 WHERE YOU CAN FIND MORE INFORMATION 16 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the SEC. The Selling Stockholder may, from time to time, sell up to 125,000,000 shares of our Common Stock, as described in this prospectus. We will not receive any proceeds from the sale by the Selling Stockholder of the securities described in this prospectus, provided, that we would receive certain proceeds in the event that the Selling Stockholder elects to exercise its Warrants. You should rely only on the information contained in this prospectus, any supplement to this prospectus or in any free writing prospectus, filed with the SEC. Neither we nor the Selling Stockholder have authorized anyone to provide you with additional information or information different from that contained in this prospectus, or any applicable prospectus supplement or any free writing prospectuses prepared by us or on our behalf and filed with the SEC. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Selling Stockholder is offering to sell our securities only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to the offering. The prospectus supplement or post-effective amendment, as the case may be, may add, up